DrugPatentWatch Database Preview

Glucagon - Generic Drug Details

« Back to Dashboard

What are the generic sources for glucagon and what is the scope of freedom to operate?

Glucagon is the generic ingredient in five branded drugs marketed by Amphastar Pharms Inc, Lilly, Eli Lilly And Co, Xeris, Novo Nordisk, and Fresenius Kabi Usa, and is included in seven NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Glucagon has seventy-nine patent family members in thirty-eight countries.

There are twelve drug master file entries for glucagon. Two suppliers are listed for this compound.

Summary for glucagon

International Patents:	79
US Patents:	5
Tradenames:	5
Applicants:	6
NDAs:	7
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	18
Clinical Trials:	713
Patent Applications:	4,392
Formulation / Manufacturing:	see details
Drug Prices:	Drug price trends for glucagon
What excipients (inactive ingredients) are in glucagon?	glucagon excipients list
DailyMed Link:	glucagon at DailyMed

See drug prices for glucagon

Recent Clinical Trials for glucagon

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Minnesota	Phase 2
University Medical Center Groningen	Phase 3
University of Minnesota	Early Phase 1

See all glucagon clinical trials

Pharmacology for glucagon

Drug Class	Antihypoglycemic Agent Gastrointestinal Motility Inhibitor
Physiological Effect	Increased Gluconeogenesis Increased Glycogenolysis Decreased GI Smooth Muscle Tone Decreased GI Motility Decreased Glycolysis

Medical Subject Heading (MeSH) Categories for glucagon

Gastrointestinal Agents

Hormones

ATC Classes for glucagon

H04AA	Glycogenolytic hormones
H04A	GLYCOGENOLYTIC HORMONES
H04	PANCREATIC HORMONES
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for glucagon

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes			Y
Eli Lilly And Co	BAQSIMI	glucagon	POWDER;NASAL	210134-001	Jul 24, 2019		RX	Yes	Yes
Lilly	GLUCAGON	glucagon hydrochloride	INJECTABLE;INJECTION	012122-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Lilly	GLUCAGON	glucagon hydrochloride	INJECTABLE;INJECTION	012122-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

International Patents for glucagon

Country	Patent Number	Estimated Expiration
China	107278154
El Salvador	2017005515
Costa Rica	20170373
European Patent Office	3352780